Quince Therapeutics (QNCX)
NASDAQ:QNCX
Top Page
Quince Therapeutics
(NASDAQ:QNCX)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.13
▼(-7.86% Downside)
Action:ReiteratedDate:04/11/26
The score is primarily constrained by very weak financial performance (pre-revenue, widening losses, accelerating cash burn, and negative equity), indicating high financing and dilution risk. Technicals remain fragile with negative MACD and longer-term downtrend signals, only modestly offset by near-oversold readings. Corporate events add significant listing-compliance and strategic-uncertainty risk despite the positive step of settling the EIB debt.
Positive Factors
Debt removal / Financial flexibility
Eliminating the ~$16.4M EIB loan materially removes a legacy liability and covenant overhang. That structural reduction in leverage enhances strategic optionality, improves negotiation flexibility for mergers or asset sales, and lowers a persistent default risk that constrained alternatives.
Negative Factors
No revenue and widening losses
The company remains pre-revenue while losses more than doubled over two years, indicating the core business is not generating operating cash inflows. Persistently larger net losses are a durable constraint that forces continual external financing and threatens equity dilution or restructuring over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt removal / Financial flexibility
Eliminating the ~$16.4M EIB loan materially removes a legacy liability and covenant overhang. That structural reduction in leverage enhances strategic optionality, improves negotiation flexibility for mergers or asset sales, and lowers a persistent default risk that constrained alternatives.
Read all positive factors
Quince Therapeutics (QNCX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$22.98M
Dividend YieldN/A
Average Volume (3M)93.96M
Price to Earnings (P/E)―
Beta (1Y)0.31
Revenue GrowthN/A
EPS Growth2.26%
CountryUS
Employees36
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.17
Shares Outstanding16,300,795
10 Day Avg. Volume221,951,364
30 Day Avg. Volume93,963,733
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-4.70
Price to Sales (P/S)0.00
P/FCF Ratio-4.02
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-177.34
Enterprise Value/Ebitda-0.33
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-6.83
Revenue Forecast (FY)N/A
Quince Therapeutics Business Overview & Revenue Model
Company Description
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides,...
How the Company Makes Money
null...
Quince Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -142.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -50.29M | -35.98M | -26.82M | -50.99M | -89.97M |
| Net Income | -83.98M | -56.83M | -31.39M | -51.66M | -89.94M |
Balance Sheet | |||||
| Total Assets | 93.52M | 114.48M | 180.20M | 103.91M | 133.23M |
| Cash, Cash Equivalents and Short-Term Investments | 17.75M | 40.78M | 75.06M | 90.18M | 106.80M |
| Total Debt | 18.36M | 14.81M | 13.81M | 453.00K | 1.16M |
| Total Liabilities | 129.24M | 84.33M | 95.12M | 3.32M | 14.64M |
| Stockholders Equity | -35.71M | 30.15M | 85.08M | 100.59M | 118.59M |
Cash Flow | |||||
| Free Cash Flow | -41.78M | -32.16M | -18.45M | -44.17M | -63.11M |
| Operating Cash Flow | -41.42M | -31.90M | -18.29M | -44.04M | -62.93M |
| Investing Cash Flow | 23.23M | 21.91M | -5.76M | 18.00M | 58.95M |
| Financing Cash Flow | 17.91M | -4.78M | 143.00K | 707.00K | 6.81M |
Quince Therapeutics Technical Analysis
Negative
0.14
Price Trends
1.43
Negative
16.35
Negative
16.66
Negative
Market Momentum
-0.51
Negative
40.92
Neutral
15.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QNCX, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 1.10, below the 50-day MA of 1.43, and below the 200-day MA of 16.66, indicating a neutral trend. The MACD of -0.51 indicates Negative momentum. The RSI at 40.92 is Neutral, neither overbought nor oversold. The STOCH value of 15.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QNCX.
Quince Therapeutics Risk Analysis
Quince Therapeutics disclosed 79 risk factors in its most recent earnings report. Quince Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Quince Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $181.96M | -4.05 | -86.91% | ― | -87.59% | 11.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $80.49M | -0.79 | -69.56% | ― | ― | 14.19% | |
44 Neutral | $163.26M | -1.32 | -30.02% | ― | ― | 25.84% | |
41 Neutral | $20.40M | -5.19 | -74.58% | ― | ― | 23.10% | |
40 Underperform | $22.98M | -2.00 | 7743.57% | ― | ― | 2.26% |
* Healthcare Sector Average
QNCX
Quince Therapeutics
1.25
-8.85
-87.62%
PLRX
Pliant Therapeutics
1.30
-0.16
-10.96%
NKTX
Nkarta
2.29
0.58
33.92%
ADAG
Adagene
3.81
2.21
138.13%
ANEB
Anebulo Pharmaceuticals
0.50
-0.45
-47.37%
Quince Therapeutics Corporate Events
Business Operations and StrategyStock Split
Quince Therapeutics Announces 1-for-10 Reverse Stock Split
Neutral
Apr 9, 2026
Quince Therapeutics, Inc. will implement a 1-for-10 reverse stock split of its common stock, approved by stockholders on June 4, 2025 and authorized by the board, with the related certificate of amendment filed in Delaware on April 9, 2026 and bec...
Business Operations and Strategy
Quince Therapeutics Eliminates EIB Debt, Boosts Flexibility
Positive
Mar 30, 2026
On March 27, 2026, Quince Therapeutics paid approximately $5.5 million to the European Investment Bank to fully settle about $16.4 million in outstanding debt tied to a 2020 finance contract and related guarantees. The company announced on March 3...
Delistings and Listing ChangesRegulatory Filings and Compliance
Quince Therapeutics Faces Nasdaq Listing Compliance Deficiencies
Negative
Mar 20, 2026
On March 16, 2026, Quince Therapeutics received notice from Nasdaq that its common stock had traded below the $1.00 minimum bid price for 30 consecutive business days, triggering a 180-day grace period to regain compliance by maintaining a closing...
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsPrivate Placements and Financing
Quince Therapeutics Pursues Reverse Merger Amid Restructuring Effort
Negative
Feb 12, 2026
On February 9, 2026, Quince Therapeutics engaged LifeSci Capital as exclusive financial adviser to help restructure the company and evaluate strategic alternatives, with an initial focus on pursuing a reverse merger to maximize shareholder value. ...
Executive/Board Changes
Quince Therapeutics Announces Significant Board of Directors Resignations
Neutral
Feb 2, 2026
On January 30, 2026, Quince Therapeutics, Inc. announced that five members of its Board of Directors—Rajiv Patni, Luca Benatti, Margi McLoughlin, Una Ryan, and June Bray—resigned from their positions effective the same day. The company...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.